IL DONG PHARMACEUTICAL CO., LTD. Logo

IL DONG PHARMACEUTICAL CO., LTD.

Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.

249420 | KO

Overview

Corporate Details

ISIN(s):
KR7249420001
LEI:
Country:
South Korea
Address:
서울특별시 서초구 바우뫼로27길 2, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IL DONG PHARMACEUTICAL CO., LTD. is a healthcare company specializing in the research, development, manufacturing, and commercialization of pharmaceutical products. The company's business spans finished drugs, active pharmaceutical ingredients (APIs), and contract manufacturing (CMO) services, utilizing its GMP-certified facilities. Its therapeutic focus includes metabolic disorders, respiratory diseases, oncology, cardiovascular conditions, and gastrointestinal diseases. Ildong Pharmaceutical is committed to innovation, advancing a robust pipeline of novel drug candidates such as oral GLP-1 agonists for diabetes/obesity and first-in-class treatments for fibrotic diseases, partly through its spin-off iLeadBMS. The company is actively expanding its global market presence through strategic partnerships, licensing, and exports.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 129.5 KB
2025-09-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 42.4 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.5 MB
2025-07-30 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 16.9 KB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.2 KB
2025-07-30 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.4 KB
2025-07-28 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.4 KB
2025-07-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 61.3 KB
2025-07-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 69.4 KB
2025-07-14 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.8 KB
2025-07-08 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.3 KB
2025-07-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 136.4 KB
2025-07-08 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 48.3 KB

Automate Your Workflow. Get a real-time feed of all IL DONG PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IL DONG PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IL DONG PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.